PharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in Ethiopia

• PharmaJet presentation will highlight the results of recent immunization studies using needle-free intradermal (ID) delivery for polio immunization campaigns.
• Data reinforces how increased coverage, decreased cost, and acceptability can be achieved with vaccines administered with the Tropis® ID System, the first and only needle-free ID delivery technology to achieve WHO prequalification.

GOLDEN, Colo. — February 19, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share the latest routine immunization study results at the 61st Annual Medical Conference and International Health Exhibition to be held on February 21-22, 2025 at the Haile Grand in Addis Ababa, Ethiopia. The presentation, entitled Intradermal needle-free vaccine delivery to reduce Ethiopia’s immunization costs and improve coverage, will be presented by Paul LaBarre, Vice President Global Business Development, PharmaJet. This event will bring together physicians from across the nation, along with representatives from Ethiopian Medical Association chapter offices, medical specialty societies, medical schools, the Ministries of Health (MoH) and Education, sister health professional associations, and partners. Intradermal (ID) vaccine administration can enable new vaccine strategies that leverage improved cross-protection, duration of immune response, and mucosal immunity. However, administration to the ID space has been difficult using traditional needle and syringe. Needle-free administration using the PharmaJet Tropis® ID System facilitates ID delivery with improved acceptability and speed of administration. Tropis, which has been used to administer polio vaccinations to more than 10 million children, is the first and only needle-free ID delivery technology to achieve WHO prequalification. A recent randomized controlled implementation study in Nigeria¹ evaluated the impact on coverage, costs, and acceptability of intradermal fractional inactivated poliovirus vaccine (fIPV) administration using the Tropis compared to the standard of care (SoC - full-dose, IPV intramuscular delivery with needle and syringe). The study demonstrated:

• Increased coverage: Among those vaccinated with Tropis, IPV2 (second dose of the inactivated polio vaccine) coverage was 11.2% higher compared to the SoC.
• Decreased total immunization costs: Incremental savings with needle-free could range from $0.07 to $1.00 per dose administered across evaluated scenarios with up to 47% total immunization cost savings compared to SoC at full scale.
• High acceptability: 94% caregivers reported high acceptability of Tropis. Healthcare worker preference for Tropis over the SoC was 95%. Tropis reduced administration time by five seconds on average compared to the SoC.

“The Nigeria study results demonstrate how using Tropis for routine immunization programs can provide significant benefits at all levels of the healthcare system,” said Paul LaBarre, Vice President of Global Business Development, PharmaJet. “Leveraging recent evidence from Tropis use in campaigns and routine immunization in Pakistan,² Somalia,³ and Nigeria,⁴ we look forward to working with the Ethiopian Ministry of Health and other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.” For more information visit the PharmaJet booth at the exhibition room or go to the PharmaJet website https://pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

¹ Data on file ² Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 ³ Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) ⁴ Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit https://pharmajet.com or contact PharmaJet here. Follow us on LinkedIn. About the Medical Conference and International Health Exhibition The Ethiopian Medical Association (EMA) is organizing its 61st Annual Medical Conference and International Health Exhibition (AMC and IHE), scheduled for February 21-22, 2025, at the Haile Grand in Addis Ababa, Ethiopia. This event will bring together physicians from across the nation, along with representatives from EMA chapter offices, medical specialty societies, medical schools, the Ministries of Health and Education, sister health professional associations, and partners. Over the course of three days, the conference and exhibition will focus on raising awareness and providing education for attendees. More than 3,000 international and local trade visitors and exhibitors are expected to participate. The International Health Exhibition will serve as a unique platform, offering local and global medical companies and specialized institutions the opportunity to showcase their products and services to a broad medical audience and the general public. It will also provide an avenue for sharing the latest advancements in medical technology and health research.